Confident Orexigen re-files Contrave NDA, expects mid-2014 decision
This article was originally published in Scrip
Executive Summary
Orexigen Therapeutics is nearing the home stretch on its road to US FDA approval for the obesity drug Contrave with the resubmission of the company's new drug application (NDA) for the prescription weight loss medicine.